---
title: "Jonathan Anderman Purchases 20,000 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) Stock"
description: "Jonathan Anderman, an insider at Compass Therapeutics, Inc. (NASDAQ:CMPX), purchased 20,000 shares at $1.54 each, totaling $30,800, on April 7th. This acquisition increased his holdings to 21,000 shar"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/235457561.md"
published_at: "2025-04-10T14:26:11.000Z"
---

# Jonathan Anderman Purchases 20,000 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) Stock

> Jonathan Anderman, an insider at Compass Therapeutics, Inc. (NASDAQ:CMPX), purchased 20,000 shares at $1.54 each, totaling $30,800, on April 7th. This acquisition increased his holdings to 21,000 shares, valued at $32,340, marking a 2,000% increase in his position. The transaction was disclosed to the SEC. Following the purchase, CMPX shares rose 3.5% to $1.63. Analysts maintain a "buy" rating for the stock, with a consensus price target of $13.38.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) insider Jonathan Anderman acquired 20,000 shares of Compass Therapeutics stock in a transaction that occurred on Monday, April 7th. The stock was purchased at an average cost of $1.54 per share, with a total value of $30,800.00. Following the completion of the purchase, the insider now owns 21,000 shares in the company, valued at $32,340. The trade was a 2,000.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Get **Compass Therapeutics** alerts:

## Compass Therapeutics Trading Up 3.5 %

-   Top 3 High-Momentum Companies Analysts Are Still Bullish On

Shares of NASDAQ:CMPX traded up $0.06 during midday trading on Tuesday, hitting $1.63. 371,628 shares of the stock were exchanged, compared to its average volume of 1,945,865. The stock has a market cap of $224.71 million, a P/E ratio of -4.39 and a beta of 1.40. Compass Therapeutics, Inc. has a twelve month low of $0.77 and a twelve month high of $4.08. The company has a 50 day moving average price of $2.73 and a 200-day moving average price of $2.11.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). On average, equities research analysts expect that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

## Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC boosted its holdings in shares of Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock valued at $25,000 after purchasing an additional 12,917 shares during the last quarter. Independent Advisor Alliance acquired a new position in shares of Compass Therapeutics in the 4th quarter valued at about $26,000. BNP Paribas Financial Markets purchased a new stake in shares of Compass Therapeutics during the 4th quarter worth about $27,000. Intech Investment Management LLC acquired a new stake in Compass Therapeutics during the 3rd quarter worth approximately $30,000. Finally, Mariner LLC purchased a new position in Compass Therapeutics in the fourth quarter valued at approximately $30,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

## Analyst Upgrades and Downgrades

CMPX has been the topic of a number of analyst reports. Jefferies Financial Group lifted their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research report on Monday, February 10th. Wedbush reaffirmed an "outperform" rating and issued a $8.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Leerink Partnrs raised shares of Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 1st. Leerink Partners raised Compass Therapeutics from a "market perform" rating to an "outperform" rating and increased their price target for the company from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Finally, D. Boral Capital restated a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $13.38.

**Get Our Latest Research Report on CMPX**

## Compass Therapeutics Company Profile

(Get Free Report)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

## Recommended Stories

-   Five stocks we like better than Compass Therapeutics
-   10 Best Airline Stocks to Buy
-   PayPal Stock: Too Cheap to Ignore, Too Strong to Miss
-   3 Grocery Stocks That Are Proving They Are Still Essential
-   Progress Software: Making Progress Driven by the AI Revolution
-   How to Use Stock Screeners to Find Stocks
-   Intel-Taiwan Semiconductor Alliance Fuels Turnaround Hopes

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in Compass Therapeutics Right Now?

Before you consider Compass Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.

While Compass Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [CMPX.US - Compass Therapeutics](https://longbridge.com/en/quote/CMPX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Compass Therapeutics: Strong Cash Position and 2026 Clinical Catalysts Underpin Reiterated Buy Rating | Analyst Joseph Pantginis of H.C. Wainwright has reiterated a Buy rating on Compass Therapeutics with a price target of $ | [Link](https://longbridge.com/en/news/271677182.md) |
| Compass Therapeutics Reports Pipeline Progress and $209 Million Cash Runway Into 2028 | Compass Therapeutics Inc. reported progress in its clinical pipeline, with $209 million in cash expected to last until 2 | [Link](https://longbridge.com/en/news/271654137.md) |
| Compass Therapeutics Grants Stock Options to New Employees Under 2025 Inducement Plan | Compass Therapeutics Inc. has granted stock options to two new employees under its 2025 Inducement Plan, approved by the | [Link](https://longbridge.com/en/news/271563491.md) |
| Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care | William Blair has initiated coverage of Compass Therapeutics, highlighting the potential of its lead drug, tovecimig, to | [Link](https://longbridge.com/en/news/271552935.md) |
| Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Compass Therapeutics Inc. :COMPASS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) | [Link](https://longbridge.com/en/news/271569050.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
